Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,055

Participants

Timeline

Start Date

June 29, 2016

Primary Completion Date

May 23, 2017

Study Completion Date

May 23, 2017

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

FF/UMEC/VI

This intervention is provided in two strips. First strip contains FF blended with lactose. It is available as dry white powder, 100 mcg per blister. Second strip contains UMEC and VI blended with lactose and magnesium stearate. It is available as dry white powder, 62.5 mcg per blister UMEC, 25 mcg per blister VI. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (2 strips with 30 blisters per strip).

DRUG

FF/VI

This intervention is provided in two strips. First strip contains FF blended with lactose. It is available as dry white powder, 100 mcg per blister. Second strip contains VI blended with lactose and magnesium stearate. It is available as dry white powder, 25 mcg per blister. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (2 strips with 30 blisters per strip).

DRUG

UMEC

This intervention is available in one strip. The strip contains UMEC blended with lactose and magnesium stearate. The formulation is available as dry white powder, 62.5 mcg per blister. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (1 strip with 30 blisters).

DRUG

Placebo

This intervention is available in one strip. The strip contains lactose. The formulation is available as dry white powder. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (1 strip with 30 blisters).

DRUG

Albuterol/salbutamol

This is a rescue medication administered via metered-dose inhaler (MDI) with a spacer which will be used when needed during the study.

Trial Locations (127)

2031

GSK Investigational Site, Randwick

2035

GSK Investigational Site, Maroubra

2145

GSK Investigational Site, Westmead

2450

GSK Investigational Site, Coffs Harbour

3011

GSK Investigational Site, Footscray

4000

GSK Investigational Site, San Miguel de Tucumán

4551

GSK Investigational Site, Golden Beach

5011

GSK Investigational Site, Woodville South

5500

GSK Investigational Site, Mendoza

6150

GSK Investigational Site, Murdoch

7600

GSK Investigational Site, Mar del Plata

13331

GSK Investigational Site, Marseille

14050

GSK Investigational Site, México DF

15562

GSK Investigational Site, Rüdersdorf

20190

GSK Investigational Site, Aguascalientes

26203

GSK Investigational Site, Wardenburg

28223

GSK Investigational Site, Pozuelo de Alarcón/Madrid

29609

GSK Investigational Site, Brest

30173

GSK Investigational Site, Hanover

31008

GSK Investigational Site, Pamplona

31224

GSK Investigational Site, Peine

31400

GSK Investigational Site, Toulouse

36039

GSK Investigational Site, Fulda

39770

GSK Investigational Site, Laredo

42651

GSK Investigational Site, Solingen

43125

GSK Investigational Site, Parma

44100

GSK Investigational Site, Guadalajara

44263

GSK Investigational Site, Dortmund

44277

GSK Investigational Site, Nantes

45070

GSK Investigational Site, Zapopan

45200

GSK Investigational Site, Zapopan

45879

GSK Investigational Site, Gelsenkirchen

48231

GSK Investigational Site, Warendorf

48431

GSK Investigational Site, Rheine

50009

GSK Investigational Site, Zaragoza

56124

GSK Investigational Site, Pisa

60389

GSK Investigational Site, Frankfurt am Main

63263

GSK Investigational Site, Neu-Isenburg

64020

GSK Investigational Site, Monterrey

64460

GSK Investigational Site, Monterrey

64710

GSK Investigational Site, Monterrey

66000

GSK Investigational Site, Perpignan

74374

GSK Investigational Site, Pringy

80131

GSK Investigational Site, Napoli

83100

GSK Investigational Site, Avellino

89407

GSK Investigational Site, Dillingen an der Donau

90146

GSK Investigational Site, Palermo

90402

GSK Investigational Site, Nuremberg

117574

GSK Investigational Site, Moscow

163000

GSK Investigational Site, Arkhangelsk

163001

GSK Investigational Site, Arkhangelsk

193231

GSK Investigational Site, Saint Petersburg

194354

GSK Investigational Site, Saint Petersburg

195030

GSK Investigational Site, Saint Petesburg

198260

GSK Investigational Site, Saint Petersburg

240564

GSK Investigational Site, Râmnicu Vâlcea

300310

GSK Investigational Site, Timișoara

400371

GSK Investigational Site, Cluj-Napoca

410028

GSK Investigational Site, Saratov

420008

GSK Investigational Site, Kazan'

420012

GSK Investigational Site, Kazan'

426063

GSK Investigational Site, Izhevsk

450071

GSK Investigational Site, Ufa

540156

GSK Investigational Site, Târgu Mureş

630102

GSK Investigational Site, Novosibirsk

634034

GSK Investigational Site, Tomsk

656024

GSK Investigational Site, Barnaul

656045

GSK Investigational Site, Barnaul

664033

GSK Investigational Site, Irkutsk

720284

GSK Investigational Site, Suceava

Unknown

GSK Investigational Site, La Plata

C1425BEN

GSK Investigational Site, Buenos Aires

C1426ABP

GSK Investigational Site, Buenos Aires

M5500CCG

GSK Investigational Site, Mendoza

03050

GSK Investigational Site, Cottbus

04109

GSK Investigational Site, Leipzg

06156

GSK Investigational Site, San Sisto (PG)

457-8511

GSK Investigational Site, Aichi

278-0004

GSK Investigational Site, Chiba

791-0281

GSK Investigational Site, Ehime

802-0083

GSK Investigational Site, Fukuoka

816-0813

GSK Investigational Site, Fukuoka

832-0059

GSK Investigational Site, Fukuoka

509-6134

GSK Investigational Site, Gifu

372-0831

GSK Investigational Site, Gunma

373-0807

GSK Investigational Site, Gunma

060-0033

GSK Investigational Site, Hokkaido

062-8618

GSK Investigational Site, Hokkaido

064-0801

GSK Investigational Site, Hokkaido

664-8540

GSK Investigational Site, Hyōgo

672-8064

GSK Investigational Site, Hyōgo

317-0077

GSK Investigational Site, Ibaraki

319-1113

GSK Investigational Site, Ibaraki

920-8530

GSK Investigational Site, Ishikawa

923-8560

GSK Investigational Site, Ishikawa

760-8538

GSK Investigational Site, Kagawa

761-8073

GSK Investigational Site, Kagawa

762-8550

GSK Investigational Site, Kagawa

210-0852

GSK Investigational Site, Kanagawa

232-0066

GSK Investigational Site, Kanagawa

236-0004

GSK Investigational Site, Kanagawa

607-8062

GSK Investigational Site, Kyoto

615-8087

GSK Investigational Site, Kyoto

515-8544

GSK Investigational Site, Mie

940-0856

GSK Investigational Site, Niigata

711-0921

GSK Investigational Site, Okayama

596-8501

GSK Investigational Site, Osaka

420-8527

GSK Investigational Site, Shizuoka

103-0027

GSK Investigational Site, Tokyo

194-0023

GSK Investigational Site, Tokyo

03810

GSK Investigational Site, Ciudad de México

82-300

GSK Investigational Site, Elblag

86-300

GSK Investigational Site, Grudziądz

25-751

GSK Investigational Site, Kielce

30-131

GSK Investigational Site, Krakow

63-400

GSK Investigational Site, Ostrow Wilekopolski

33-100

GSK Investigational Site, Tarnów

020125

GSK Investigational Site, Bucharest

030303

GSK Investigational Site, Bucharest

115 280

GSK Investigational Site, Moscow

130-709

GSK Investigational Site, Seoul

152-703

GSK Investigational Site, Seoul

156-755

GSK Investigational Site, Seoul

442-723

GSK Investigational Site, Suwon

220-701

GSK Investigational Site, Wonju, Gangwon-do,

08003

GSK Investigational Site, Barcelona

06800

GSK Investigational Site, Mérida (Badajoz)

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02729051 - Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter